兆科眼科-B(06622)拟与东生华制药于台湾地区共同推进BRIMOCHOL?PF的临床导论及未来商业化

Group 1 - The core viewpoint of the article is that Zhaoke Ophthalmology-B (06622) has entered into a strategic partnership with Dongshenghua Pharmaceutical to jointly advance the clinical introduction and future commercialization of BRIMOCHOL PF in Taiwan [1] - Under the agreement, Zhaoke grants Dongshenghua exclusive distributor rights for the registration, importation, promotion, distribution, marketing, and sales of BRIMOCHOL PF in Taiwan [1] - The developer of BRIMOCHOL PF, Tenpoint Therapeutics, Ltd., announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026, under the Prescription Drug User Fee Act (PDUFA) [1]